BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 25998048)

  • 1. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.
    Ghosh S; Kinsey SG; Liu QS; Hruba L; McMahon LR; Grim TW; Merritt CR; Wise LE; Abdullah RA; Selley DE; Sim-Selley LJ; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2015 Aug; 354(2):111-20. PubMed ID: 25998048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
    Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice.
    Schlosburg JE; Kinsey SG; Ignatowska-Jankowska B; Ramesh D; Abdullah RA; Tao Q; Booker L; Long JZ; Selley DE; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2014 Aug; 350(2):196-204. PubMed ID: 24849924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.
    Hruba L; Seillier A; Zaki A; Cravatt BF; Lichtman AH; Giuffrida A; McMahon LR
    J Pharmacol Exp Ther; 2015 May; 353(2):261-8. PubMed ID: 25711338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.
    Owens RA; Ignatowska-Jankowska B; Mustafa M; Beardsley PM; Wiley JL; Jali A; Selley DE; Niphakis MJ; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2016 Aug; 358(2):306-14. PubMed ID: 27307500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.
    Ignatowska-Jankowska BM; Ghosh S; Crowe MS; Kinsey SG; Niphakis MJ; Abdullah RA; Tao Q; O' Neal ST; Walentiny DM; Wiley JL; Cravatt BF; Lichtman AH
    Br J Pharmacol; 2014 Mar; 171(6):1392-407. PubMed ID: 23848221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
    Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
    Ignatowska-Jankowska B; Wilkerson JL; Mustafa M; Abdullah R; Niphakis M; Wiley JL; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2015 May; 353(2):424-32. PubMed ID: 25762694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
    Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
    J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
    Kinsey SG; Wise LE; Ramesh D; Abdullah R; Selley DE; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2013 Jun; 345(3):492-501. PubMed ID: 23412396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.
    Thomas A; Okine BN; Finn DP; Masocha W
    Biomed Pharmacother; 2020 Sep; 129():110456. PubMed ID: 32603895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
    Ramesh D; Ross GR; Schlosburg JE; Owens RA; Abdullah RA; Kinsey SG; Long JZ; Nomura DK; Sim-Selley LJ; Cravatt BF; Akbarali HI; Lichtman AH
    J Pharmacol Exp Ther; 2011 Oct; 339(1):173-85. PubMed ID: 21719468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
    Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.
    Ramesh D; Gamage TF; Vanuytsel T; Owens RA; Abdullah RA; Niphakis MJ; Shea-Donohue T; Cravatt BF; Lichtman AH
    Neuropsychopharmacology; 2013 May; 38(6):1039-49. PubMed ID: 23303065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
    Wilkerson JL; Niphakis MJ; Grim TW; Mustafa MA; Abdullah RA; Poklis JL; Dewey WL; Akbarali H; Banks ML; Wise LE; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2016 Apr; 357(1):145-56. PubMed ID: 26791602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid CB
    Leonard MZ; Alapafuja SO; Ji L; Shukla VG; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
    J Pharmacol Exp Ther; 2017 Dec; 363(3):314-323. PubMed ID: 28947487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
    Kinsey SG; O'Neal ST; Long JZ; Cravatt BF; Lichtman AH
    Pharmacol Biochem Behav; 2011 Mar; 98(1):21-7. PubMed ID: 21145341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat.
    Woodhams SG; Wong A; Barrett DA; Bennett AJ; Chapman V; Alexander SP
    Br J Pharmacol; 2012 Dec; 167(8):1609-19. PubMed ID: 22924700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice.
    Wise LE; Long KA; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
    ACS Chem Neurosci; 2012 May; 3(5):369-78. PubMed ID: 22860205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling.
    Pan B; Wang W; Long JZ; Sun D; Hillard CJ; Cravatt BF; Liu QS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):591-7. PubMed ID: 19666749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.